Why Reactive Approaches to Antimicrobial Resistance Are Failing
Resistance rates are accelerating, and the patients who can least afford treatment failure—immunocompromised, transplant, oncology—face the highest stakes.
Impact
tests that forecast resistance
The Science Behind Antimicrobial Resistance
Understanding how bacteria outsmart our best defenses
Mutation
Bacteria develop resistance to antimicrobials through genetic mutations that allow them to survive drug exposure.
DNA Acquisition
Bacteria acquire resistance genes from other organisms, rapidly spreading resistance mechanisms across species.
Rapid Evolution
Bacteria develop multidrug resistance (MDR) and evolve faster than we can develop new antimicrobials.
We have a learning system gap
We don't just need faster results, we need better information.
Snapshot diagnostics, not foresight
Current results describe susceptibilities as a moment in time, when they are dynamic, constantly in flux, and subject to evolution and population dynamics. No currently available diagnostic technology appreciates this and captures information regarding pathogen evolution under drug pressure.
Treatment-emergent resistance is a blind spot
Resistance often emerges during therapy, especially in high-risk patients and pathogens. We lack an early warning signal to identify which pathogens are on the brink of acquiring new resistance, until treatment fails and it's clinically obvious.
No learning system linking evolution to outcomes
Genomics, microbiology, prescribing, and outcomes live in silos. Without a feedback loop that connects pathogen evolution to real patient trajectories, hospitals can't continuously improve decisions—and drug development can't systematically design for resistance avoidance.
Breaking the Reactive Cycle
From waiting for failure to forecasting it before it happens
New Clinical Signal
First forecast of treatment-emergent resistance risk to help prevent failures in vulnerable patients.
Results in 24 Hours
Actionable insights designed for stewardship to optimize appropriate therapy.
Learn Continuously
Build the intelligence layer that links bacterial evolution to patient outcomes across health systems.
The technology to analyze bacterial genomes exists. What's been missing is the ability to translate genomic data into clinically actionable insights.
Informuta's ApproachWe pioneered bacterial mutational signature mapping to forecast resistance evolution. Our biologically explainable AI delivers clinician-ready forecasts that transform antimicrobial prescribing from reactive to predictive.
Resources & Further Reading
Learn more from leading health organizations
Stop Resistance Before It Starts
For the patients who can't afford treatment failure, forecasting resistance before therapy changes everything.